Durvalumab in Pediatric and Adolescent Patients

Summary

This clinical trial is the first clinical trial to study Durvalumab, a checkpoint inhibitor which stimulates the patient's own immune system to act against cancer cells in children and adolescents. This trial will assess the safety and tolerability of Durvalumab in children and adolescents and also study how Durvalumab is processed in their bodies.

Timeline

Start

2016-07

Primary completion

2022-11-30

Completion

2023-04-30

Drugs

Indications